Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.
This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
in Tübingen and Munich, Germany and Houston, Texas
covering major solid and liquid tumors
proprietary technology platforms
proprietary development programs – 4 of which are in clinical development
targets covering major solid and liquid tumors
at a Glance
Unlocking new T cell receptor-based immunotherapies by identifying true targets:
Immatics brings together a breadth of technologies matched with deep knowledge of cancer-specific targets and TCRs to achieve the next advance in immunotherapy.
Immatics’ approach towards the goal of opening new avenues of treatment for cancer patients starts with the discovery and validation of true targets (using the XPRESIDENT® platform). In the next step, Immatics identifies, engineers and validates delivering the power of T cells to cancer patients.
Since its foundation in 2000 as a spin out from H.G. Rammensee’s laboratory at University of Tübingen, Germany, Immatics has revolutionized the identification of tumor-associated pHLA targets, which are recognized by T cells. Identifying true cancer targets that are presented on tumor tissue but not on healthy cells and the subsequent discovery, selection, and engineering of a therapeutic TCR are central to Immatics‘ mission: Delivering the power of T cells to cancer patients and advance the next wave in cancer immunotherapy.
In 2015, Immatics and MD Anderson Cancer Center launched Immatics US, Inc. in Houston, Texas as a joint venture to develop transformative Adoptive Cell Therapies.